IL17R inhibitor - Dompe Farmaceutici
Latest Information Update: 24 May 2022
At a glance
- Originator Dompe Farmaceutici
- Class Anti-inflammatories; Drug conjugates; Eye disorder therapies; Peptides
- Mechanism of Action IL17A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Inflammation
Most Recent Events
- 26 Apr 2022 IL17R inhibitor - Dompe Farmaceutici is available for licensing as of 22 Apr 2022. https://www.dompe.com/en/partners
- 22 Apr 2022 Early research in Autoimmune disorders in Italy (Parenteral)
- 22 Apr 2022 Early research in Inflammation in Italy (Parenteral)